The SEC has resolved insider trading allegations with a Massachusetts resident concerning Sage Therapeutics, Inc, after his alleged liquidation of shares in the company on the basis of “extremely restricted” FDA-related information.
According to the SEC’s complaint, Brian Suthoff allegedly avoided losses of nearly $20,000 by trading in advance of

